In a surprising turn of events, Regeneron has announced its acquisition of 23andMe for $256 million following the company's bankruptcy. The pharma giant aims to leverage 23andMe's vast customer data for drug discovery while prioritizing privacy and security.
In a groundbreaking feat, Colossal Biosciences has successfully resurrected the dire wolf, bringing three pups into the world using advanced cloning techniques. This achievement marks a significant milestone in de-extinction efforts and conservation science.
